Cambridge Healthtech Institute’s 5th Annual

Immunomodulatory Approaches

Harnessing the Immune Response

10-11 March, 2020

 

With an abundance of immunotherapies and increasing biomarker availability, there are ever more choices for oncologists looking to employ the immune system in their treatment plans. The tumour microenvironment, and all its heterogeneity, represents a huge challenge in stratifying patient populations and selecting immunomodulatory therapies. At the 5th Annual Immunomodulatory Approaches conference we will discuss how immune cells and cytokines can be activated or suppressed to elicit a desired treatment response with a focus on T cell effectors, myeloid-derived suppressor cells and bispecific antibody Fc engagement.

Preliminary Agenda

ANTIBODY-DRUG CONJUGATES

Antibody-Cytokine Fusions: From Discovery to Phase III Clinical Trials

Dario Neri, PhD, Professor, Biomacromolecules, Chemistry and Applied Biosciences, ETH Zürich

TARGETING INNATE IMMUNE CELLS

Re-Activating Macrophages in the Tumour Microenvironment with Anti-Tumour IgE Antibodies

Sophia N. Karagiannis, BA, MS, PhD, Reader, Translational Cancer Immunology, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London

Optimising STING Agonists for Cancer Therapy

Stephen A. Beers, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, University of Southampton

From Local Immune Modulation to Systemic Tumor Control: Harnessing Dendritic Cells in the Fight Against Melanoma

Tanja de Gruijl, PhD, Professor and Chair of Translational Tumor Immunology, Department of Medical Oncology, VU University Medical Center Amsterdam

IMMUNE MODULATING BISPECIFIC ANTIBODIES

Novel PD-1 Bispecific Antibodies for Cancer Immunotherapy

Laura Codarri Deak, PhD, Principal Scientist, Team and Research Project Leader in Cancer Immunotherapy, Roche Pharma

Next Generation Bispecifics for Cancer Immunotherapy

Michelle Morrow, PhD, VP, Preclinical Translational Pharmacology, F-Star

T CELL-ENGAGING CONSTRUCTS

CB213: A Second-Generation Checkpoint Inhibitor Optimally Configured for Therapeutic Efficacy

James Legg, PhD, Vice President, R&D, Crescendo Biologics

ATOR-1017, a 4-1BB Antibody Developed for Tumor-Directed Immunotherapy of Cancer

Karin Enell Smith, PhD, Senior Scientist, Preclinical Development, Alligator Bioscience




For more details on the conference, please contact:
Joel Hornby, BSc Hons

Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-1816
Email: jhornby@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

 

 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag